Karyopharm Therapeutics (NASDAQ:KPTI) Given Outperform Rating at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating reiterated by research analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $3.00 price objective on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 401.34% from the company’s previous close.

A number of other research firms have also weighed in on KPTI. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Finally, Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Down 1.9 %

Shares of NASDAQ KPTI opened at $0.60 on Thursday. The firm has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $0.76. The stock has a market capitalization of $75.51 million, a price-to-earnings ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 52 week low of $0.53 and a 52 week high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, equities research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $27,000. Focus Partners Wealth acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at about $31,000. TD Waterhouse Canada Inc. purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $32,000. Two Sigma Advisers LP increased its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $85,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).